What is targeted therapy for dog cancer?

It's treatment matched to the specific genetic mutations driving an individual dog's tumor. A tissue sample is sequenced, mutations are identified, and drugs designed to block those mutations are prescribed, often as a pill given at home.

How is it different from chemotherapy?

Chemotherapy attacks all fast-dividing cells in the body, healthy ones included, which is why it causes broad side effects. Targeted therapy aims to inhibit only the cells carrying a particular mutation, which can mean a gentler experience.

Are the drugs FDA-approved for dogs?

With one exception, the drugs used were originally developed for human cancers. A 1994 federal law lets veterinarians prescribe FDA-approved human drugs 'extra-label' for pets, which is what makes this approach possible.

Illness & Conditions

Your Dog's Cancer Pill Was Built for Humans First. That's Exactly the Point.

Precision cancer medicine is moving from human oncology into the vet's office. Here's how gene-matched targeted therapy for dogs actually works, and what it can and can't do.

By Dr. Ravi Mehta, Veterinary Nutritionist

August 18, 2026 · 6 min read

Link copied

Cancer is the word no pet owner wants to hear in an exam room, and the odds make it a word many of us eventually will. Roughly one in four dogs develops some kind of cancer over a lifetime, and dogs and people are diagnosed at strikingly similar rates. For most of the last century, a canine diagnosis meant one of two roads: chemotherapy or radiation, both powerful, both blunt.

The real shift underway isn’t a new drug. It’s a new question. Instead of asking “what kind of cancer is this,” precision oncology asks “what is broken inside these specific cells,” and then goes after that. It’s the approach that reshaped human cancer care over the past two decades, and it is now arriving in veterinary medicine. That’s the story worth understanding, because it changes what an owner can reasonably hope for, and it comes with real limits that the marketing tends to skip.

Why timing has always been the enemy

With most cancers, the clock is the opponent. If you can’t get your dog seen quickly when something looks wrong, or if starting treatment drags out to a month or more after the diagnosis, the outcomes, both length and quality of life, tend to slide. Traditional chemotherapy and radiation are demanding to schedule, hard on the body, and often require repeated clinic visits.

That friction is part of why an at-home, pill-based option is appealing. One California company, One Health, launched a service called FidoCure that uses genetic testing to find a tumor’s cancer-driving mutations and then matches a customized therapy to them. The treatment is delivered in pill form and can be given at home, and the company describes it as cheaper than conventional chemo. Most pet insurance plans cover it.

The logic: hit the mutation, spare the rest

The appeal of targeted therapy comes down to precision. Conventional chemotherapy kills rapidly dividing cells across the board, which is why it hits healthy tissue and produces such broad side effects. Targeted drugs are designed to inhibit the growth of cells carrying a specific mutation, leaving more of the body alone.

“The mental model people carry is chemo, which is essentially carpet-bombing,” says Dr. Ravi Mehta. “Precision oncology is closer to handing the immune system a street address. When it works, you get more effect on the tumor and less collateral damage to the dog, and that quality-of-life difference is often what families notice first.”

There is a reason this crossover is even possible, and it runs both directions. Because dogs and humans develop many of the same cancers, researchers have long studied one species to understand the other. The National Cancer Institute has run canine-focused clinical trials as part of its comparative oncology work for more than two decades, looking for treatments that preserve dogs’ quality of life and translate back to human patients. Most of the safety data behind these targeted drugs was generated in human medicine first, which is exactly why they can be brought to dogs with a reasonable understanding of how they behave.

How the process actually works

The mechanics are more straightforward than they sound. A vet, typically a board-certified oncologist, ships off a piece of tumor tissue to be gene-sequenced at a CLIA-certified lab. Back comes a report tailored to that one dog and its cancer, flagging the mutations that could steer treatment and naming FDA-approved drugs that fit.

Here is the legal piece that makes it work: with a single exception, every veterinary oncology drug used this way was built for human cancers first. Vets are allowed to prescribe them off-label (the industry term is “extra-label”) under the Animal Medicinal Drug Use Clarification Act of 1994, a law that lets them use FDA-approved human drugs in animals without a separate approval process. A compounding pharmacy then titrates each drug to the individual dog’s needs, sometimes adding a flavor, with beef liver reportedly a favorite.

The therapy is intended for cases where a tumor carries a specific mutation that maps to a precise drug. In practice, it is also used for dogs whose cancer has spread, is inoperable, or stopped responding to other treatments. While all cancers are technically eligible, hemangiosarcoma has made up the bulk of cases so far, along with bladder cancer and rarer canine cancers like histiocytic sarcoma. By the company’s own account, roughly half of its cases arrive only after traditional therapies have failed, which is worth keeping in mind when you read its survival numbers.

What the early numbers said, and what to make of them

Of an early cohort of 38 dogs all deemed terminal, 24 (about 63 percent) were still living at the time the company reported, each one treated somewhere between two and thirteen months prior. That is a genuinely hopeful signal, but read it carefully: it’s a small, early, self-reported group, many of whom came to the service already out of other options. Early survival snapshots like this are a reason for cautious optimism, not a guarantee, and any honest conversation with your oncologist should treat them that way.

Know the warning signs first

None of this matters if the cancer is caught late, and precision or not, early detection still drives outcomes. The American Veterinary Medical Association flags a set of signs that warrant a prompt vet visit: abdominal swelling; bleeding from the mouth, nose, or other openings; difficulty breathing; difficulty eating; lumps, bumps, or discolored skin; wounds that won’t heal; persistent vomiting or diarrhea; sudden weight changes; unexplained swelling, heat, pain, or lameness; and any visible mass. A lump that’s new, growing, or changing is worth a same-week appointment, not a wait-and-see.

A wider field than one company

FidoCure is one player in a fast-moving space, not the whole story. Elias Animal Health has developed a platform that combines a cancer vaccine pretreatment with activated “killer” T-cell immunotherapy. At Cornell’s College of Veterinary Medicine, researchers have studied a lymphoma common to both dogs and people, using metabolomics, the chemistry of what’s actually happening inside tumor cells, alongside DNA data to design treatment. Genetic data shows what mutations a tumor carries; the metabolic profile shows what those cells are doing with them. Combining the two is where a lot of the next decade’s progress is likely to come from.

What’s new since this was written

The evidence base got meaningfully stronger. In 2025, researchers published a peer-reviewed study in Scientific Reports analyzing 508 pet dogs with splenic hemangiosarcoma treated through the precision-medicine platform, and it linked specific genomic biomarkers to real survival differences, a much larger and more rigorous dataset than the early 38-dog snapshot. Hemangiosarcoma is one of the deadliest and fastest canine cancers, so credible survival signals there matter.

The other quiet shift is the role of data itself. These platforms now learn from thousands of treated cases at once, using each dog’s outcome to sharpen the next dog’s recommendation. Individual stories can be striking, one widely shared case involved a dog named Forrest, given about a month to live after a splenic cancer diagnosis, who went on to live nearly four more years. Stories like that are the exception rather than the promise, but the growing pool of real-world outcomes is what’s slowly turning precision oncology from a hopeful idea into a measurable one.

If your dog is facing a cancer diagnosis, this is a conversation to have with a board-certified veterinary oncologist, who can tell you whether your dog’s specific tumor is a candidate and weigh it honestly against the alternatives.